Question special
Lead Moderator

Hi everyone and welcome to the NEJM Open Group Forum discussion on the article, “Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention.” My name is Leonard and I will serve as the moderator for this thread. I would first like to congratulate Dr. Fowler et al. on designing and implementing the PROMISE study, which was conducted at 14 sites in 7 countries with over 3000 HIV-infected women. The study found that antenatal antiretroviral therapy (ART) resulted in significantly lower early HIV transmission than zidovudine/single-dose nevirapine (ZDV/sdNVP) alone, but higher risk of adverse maternal/neonatal outcomes.

I would also like to welcome and thank our featured experts who have agreed to spend the time to share their knowledge and insights on this topic. The use of this forum is meant to encourage discussion and questions from individuals with varying levels of expertise. All guests are welcome to ask questions and I encourage all our authors and experts to answer any questions that are posed. I hope this forum will exciting place for interactive dialogue over the next 10 days. Welcome!